IMPORTANT EQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, Sept. 12, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA) regarding possible violations of federal securities laws between November 15, 2016 and August 2, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the October 23, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Teva made false and/or misleading statements and/or failed to disclose that the poor performance of its U.S. generics business resulted in recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting the Company’s dividend by 75%. Upon this news, shares of Teva dropped in value materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esquire, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/